NEW APPROACHES TO COMBINED THERAPY OF IRRITATIVE SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
- Авторлар: Ergakov D.V1, Martov A.G1,2,3
-
Мекемелер:
- A.I. Burnazyan SRC FMBC, FMBA of Russia
- GBUZ «City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow»
- M.V. Lomonosov Moscow State University
- Шығарылым: № 2 (2021)
- Беттер: 40-45
- Бөлім: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312555
- DOI: https://doi.org/10.18565/urology.2021.2.40-45
- ID: 312555
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
Авторлар туралы
D. Ergakov
A.I. Burnazyan SRC FMBC, FMBA of Russia
Email: dergakov@mail.ru
Ph.D., associate professor at the Department of Urology and Andrology Moscow, Russia
A. Martov
A.I. Burnazyan SRC FMBC, FMBA of Russia; GBUZ «City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow»; M.V. Lomonosov Moscow State University
Email: martovalex@mail.ru
Ph.D., MD, professor, Honored Physician of the Russian Federation, Head of the Department of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia, Head of the urologic department of GBUZ «City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow», Medical Research Center, M.V. Lomonosov Moscow State University Moscow, Russia
Әдебиет тізімі
- Su S., Lin J., Liang L., Liu L., Chen Z., Gao Y. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and metaanalysis. Medicine 2020;99:4(e18802).
- Peyronnet B., Mironska E., Chapple C. et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol 2019;75:988.
- Cindolo L., Pirozzi L., Fanizza C. et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68(3):418-425.
- Ергаков Д.В., Мартов А.Г. Комбинированная терапия расстройств мочеиспускания после трансуретральной резекции предстательной железы. Урология. 2018;1:62-70, https://dx.doi.org/10.18565/ urology.2018.1.62-70
- Thomas D., Chughtai B., Kini M., Te A. Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs. 2017;22(3):201- 212.
- Kelleher C., Hakimi Z., Zur R. et al: Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324.
- Füllhase C., Schneider M.P. 5-ARI and combination therapy. Urol Clin North Am. 2016;43(3):325-336.
- Van Kerrebroeck P., Haab F., Angulo J.C. et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64:398.
- Rees J., Foley S., Huang M., et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourology and Urodynamics. 2019;38:981-989. https://doi. org/10.1002/nau.23944
- Muderrisoglu A.E., Becher K.F., Madersbacher S. et al. Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf. 2019;18:915.
- Kakizaki H., Lee K.S., Yamamoto O. et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2019. Doi.org/10.1016/j.euf.2019.10.019.
- Kaplan S., Herschorn S., McVary K.T. et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J. Urol 2020;203:1163-1171. https://doi.org/10.1097/JU.0000000000000738